NCT02632396View on ClinicalTrials.gov

Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

August 15, 2023

Study Completion Date

August 31, 2024

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Ixazomib

Given PO

BIOLOGICAL

Rituximab

Given IV

Trial Locations (2)

30322

Emory University/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER